vs
南玻集团（CSGS）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是Esperion Therapeutics, Inc.的1.9倍（$323.1M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 2.0%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 4.6%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
CSGS vs ESPR — 直观对比
营收规模更大
CSGS
是对方的1.9倍
$168.4M
营收增速更快
ESPR
高出141.7%
2.0%
两年增速更快
ESPR
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $168.4M |
| 净利润 | $7.0M | — |
| 毛利率 | 50.0% | — |
| 营业利润率 | 9.0% | 50.6% |
| 净利率 | 2.2% | — |
| 营收同比 | 2.0% | 143.7% |
| 净利润同比 | -79.7% | — |
| 每股收益（稀释后） | $0.24 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSESPR
| Q4 25 | $323.1M | $168.4M | ||
| Q3 25 | $303.6M | $87.3M | ||
| Q2 25 | $297.1M | $82.4M | ||
| Q1 25 | $299.5M | $65.0M | ||
| Q4 24 | $316.7M | $69.1M | ||
| Q3 24 | $295.1M | $51.6M | ||
| Q2 24 | $290.3M | $73.8M | ||
| Q1 24 | $295.1M | $137.7M |
净利润CSGSESPR
| Q4 25 | $7.0M | — | ||
| Q3 25 | $20.5M | $-31.3M | ||
| Q2 25 | $12.3M | $-12.7M | ||
| Q1 25 | $16.1M | $-40.5M | ||
| Q4 24 | $34.5M | — | ||
| Q3 24 | $19.1M | $-29.5M | ||
| Q2 24 | $13.8M | $-61.9M | ||
| Q1 24 | $19.5M | $61.0M |
毛利率CSGSESPR
| Q4 25 | 50.0% | — | ||
| Q3 25 | 48.1% | — | ||
| Q2 25 | 49.5% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 51.3% | — | ||
| Q3 24 | 49.4% | — | ||
| Q2 24 | 47.3% | — | ||
| Q1 24 | 46.5% | — |
营业利润率CSGSESPR
| Q4 25 | 9.0% | 50.6% | ||
| Q3 25 | 10.0% | -11.4% | ||
| Q2 25 | 10.0% | 8.6% | ||
| Q1 25 | 9.8% | -34.0% | ||
| Q4 24 | 13.4% | -6.4% | ||
| Q3 24 | 10.8% | -31.0% | ||
| Q2 24 | 8.8% | 3.5% | ||
| Q1 24 | 10.8% | 52.5% |
净利率CSGSESPR
| Q4 25 | 2.2% | — | ||
| Q3 25 | 6.7% | -35.9% | ||
| Q2 25 | 4.1% | -15.4% | ||
| Q1 25 | 5.4% | -62.2% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 6.5% | -57.2% | ||
| Q2 24 | 4.8% | -83.9% | ||
| Q1 24 | 6.6% | 44.3% |
每股收益（稀释后）CSGSESPR
| Q4 25 | $0.24 | $0.32 | ||
| Q3 25 | $0.73 | $-0.16 | ||
| Q2 25 | $0.44 | $-0.06 | ||
| Q1 25 | $0.57 | $-0.21 | ||
| Q4 24 | $1.20 | $-0.14 | ||
| Q3 24 | $0.67 | $-0.15 | ||
| Q2 24 | $0.48 | $-0.33 | ||
| Q1 24 | $0.68 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $167.9M |
| 总债务越低越好 | $539.5M | — |
| 股东权益账面价值 | $283.7M | $-302.0M |
| 总资产 | $1.5B | $465.9M |
| 负债/权益比越低杠杆越低 | 1.90× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGSESPR
| Q4 25 | $180.0M | $167.9M | ||
| Q3 25 | $158.4M | $92.4M | ||
| Q2 25 | $145.9M | $86.1M | ||
| Q1 25 | $136.0M | $114.6M | ||
| Q4 24 | $161.8M | $144.8M | ||
| Q3 24 | $118.4M | $144.7M | ||
| Q2 24 | $110.4M | $189.3M | ||
| Q1 24 | $120.8M | $226.6M |
总债务CSGSESPR
| Q4 25 | $539.5M | — | ||
| Q3 25 | $538.6M | — | ||
| Q2 25 | $537.8M | — | ||
| Q1 25 | $537.6M | — | ||
| Q4 24 | $538.5M | — | ||
| Q3 24 | $539.5M | — | ||
| Q2 24 | $540.5M | — | ||
| Q1 24 | $541.5M | — |
股东权益CSGSESPR
| Q4 25 | $283.7M | $-302.0M | ||
| Q3 25 | $289.5M | $-451.4M | ||
| Q2 25 | $290.7M | $-433.5M | ||
| Q1 25 | $283.1M | $-426.2M | ||
| Q4 24 | $282.6M | $-388.7M | ||
| Q3 24 | $288.4M | $-370.2M | ||
| Q2 24 | $273.3M | $-344.2M | ||
| Q1 24 | $269.3M | $-294.3M |
总资产CSGSESPR
| Q4 25 | $1.5B | $465.9M | ||
| Q3 25 | $1.5B | $364.0M | ||
| Q2 25 | $1.4B | $347.1M | ||
| Q1 25 | $1.4B | $324.0M | ||
| Q4 24 | $1.5B | $343.8M | ||
| Q3 24 | $1.4B | $314.1M | ||
| Q2 24 | $1.4B | $352.3M | ||
| Q1 24 | $1.3B | $373.1M |
负债/权益比CSGSESPR
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.86× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.90× | — | ||
| Q4 24 | 1.91× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 2.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | — |
| 自由现金流率自由现金流/营收 | 17.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | 0.0% |
| 现金转化率经营现金流/净利润 | 8.46× | — |
| 过去12个月自由现金流最近4个季度 | $141.4M | — |
8季度趋势，按日历期对齐
经营现金流CSGSESPR
| Q4 25 | $59.2M | $45.2M | ||
| Q3 25 | $47.9M | $-4.3M | ||
| Q2 25 | $37.3M | $-31.4M | ||
| Q1 25 | $11.5M | $-22.6M | ||
| Q4 24 | $82.5M | $-35.0M | ||
| Q3 24 | $39.5M | $-35.3M | ||
| Q2 24 | $43.1M | $-7.2M | ||
| Q1 24 | $-29.4M | $53.8M |
自由现金流CSGSESPR
| Q4 25 | $55.8M | — | ||
| Q3 25 | $43.9M | — | ||
| Q2 25 | $34.6M | — | ||
| Q1 25 | $7.1M | — | ||
| Q4 24 | $76.6M | — | ||
| Q3 24 | $32.0M | $-35.5M | ||
| Q2 24 | $38.8M | $-7.3M | ||
| Q1 24 | $-34.1M | $53.8M |
自由现金流率CSGSESPR
| Q4 25 | 17.3% | — | ||
| Q3 25 | 14.5% | — | ||
| Q2 25 | 11.6% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 10.8% | -68.7% | ||
| Q2 24 | 13.4% | -9.9% | ||
| Q1 24 | -11.6% | 39.0% |
资本支出强度CSGSESPR
| Q4 25 | 1.1% | 0.0% | ||
| Q3 25 | 1.3% | 0.0% | ||
| Q2 25 | 0.9% | 0.0% | ||
| Q1 25 | 1.5% | 0.0% | ||
| Q4 24 | 1.9% | 0.0% | ||
| Q3 24 | 2.5% | 0.3% | ||
| Q2 24 | 1.5% | 0.1% | ||
| Q1 24 | 1.6% | 0.1% |
现金转化率CSGSESPR
| Q4 25 | 8.46× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 3.04× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.12× | — | ||
| Q1 24 | -1.51× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
